ABANZA, a company focused on next-generation soft-tissue repair solutions, today announced that the U.S. Food and Drug ...
U.S. orthopedic soft tissue repair hit $2.3B in 2024, projected near $3.4B by 2031, driven by outpatient arthroscopy ...
ABANZA, a company focused on next-generation soft-tissue repair solutions, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for QuadLock(TM), its new ...